Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report [Seeking Alpha]
Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
Company Research
Source: Seeking Alpha
reported that at four individuals have been interviewed about the possibility some side effects -- including suicidal thoughts -- were not reported. The newspaper noted that one person interviewed was asked about the techniques used in giving the therapy, called midomafetamine. Earlier in August, the FDA issued a Complete Response Letter to Lykos on the drug and asked the company to conduct an additional trial. Less than a week later, Lykos said it would lay off 75% of its workforce. Publicly traded psychedelic-focused drug developers include Mind Medicine ( NASDAQ: MNMD ), Atai Life Sciences ( NASDAQ: ATAI ), COMPASS Pathways ( NASDAQ: CMPS ), Cybin ( CYBN ), and GH Research ( GHRS Nano-caps include 180 Life Sciences ( ATNF ), Enveric Biosciences ( ENVB ), Seelos Therapeutics ( NASDAQ: SEEL ), SciSparc ( SPRC ), Bright Minds Biosciences ( DRUG ), and Clearmind Medicine ( CMND Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Mind Medicine (MindMed) Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $16.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- MindMed Announces New Employee Inducement GrantsBusiness Wire
- MindMed to Participate in September Investor ConferencesBusiness Wire
- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target raised by analysts at HC Wainwright from $35.00 to $55.00. They now have a "buy" rating on the stock.MarketBeat
- Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD [Seeking Alpha]Seeking Alpha
MNMD
Earnings
- 8/13/24 - Beat
MNMD
Sec Filings
- 9/25/24 - Form 144
- 9/25/24 - Form 4
- 9/25/24 - Form 4
- MNMD's page on the SEC website